While cell death and ALS disease onset in mice are initiated by RIPK1 (3), NLRP3 further contributes to disease progression and inflammation (49–51), strengthening the potential benefit for dual therapy. Here, NLRP3 is linked to amyotrophic lateral sclerosis.